[
  {
    "clause_index": 19,
    "start_char": 7495,
    "end_char": 9339,
    "original": "(a) any Competitor (i) becomes the beneficial owner, directly or indirectly, of shares of capital stock or other interests (including partnership interests) of the Licensee then outstanding and normally entitled (without regard to the occurrence of any contingency) to vote in the election of the directors, managers or similar supervisory positions ( Voting Stock ) of such Party representing more than fifty percent (50%) of the total voting power of all outstanding classes of Voting Stock of the Licensee or (ii) has the power, directly or indirectly, to appoint a majority of the Licensee\u2019s managing directors or to elect a majority of the members of the Licensee\u2019s board of directors, supervisory board or similar governing body ( Board of Directors )\u037e or Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020 Confidential Execution Version (b) the Licensee enters into a merger, consolidation or similar transaction with a Competitor (whether or not such Party is the surviving entity) and as a result of such merger, consolidation or similar transaction (i) the managing directors or the members of the Board of Directors of the Licensee immediately prior to such transaction constitute less than a majority of the managing directors or the members of the Board of Directors of the Licensee or such surviving person immediately following such transaction or (ii) the persons that beneficially owned, directly or indirectly, the shares of Voting Stock of the Licensee immediately prior to such transaction cease to beneficially own, directly or indirectly, shares of Voting Stock of the Licensee representing a majority of the total voting power of all outstanding classes of Voting Stock of the surviving person in substantially the same proportions as their ownership of Voting Stock of the Licensee immediately prior to such transaction.",
    "ollama_generated": "(a) If a Competitor:\n\n   (i) acquires, either directly or indirectly, a controlling interest (representing more than fifty percent (50%)) in the voting stock or other interests (including partnership interests) of the Licensee that entitles them to control the election of directors, managers, or similar supervisory positions within the Company, without regard to any contingencies; or\n\n   (ii) obtains the power, directly or indirectly, to appoint a majority of the Licensee's executive officers, or to elect a majority of the members of the board of directors, supervisory board, or similar governing body (Board of Directors), then:\n\n      The obligations under this agreement shall be considered fulfilled by the Licensee and no further actions are required.\n\n(b) In case the Licensee undergoes a merger, consolidation, or similar transaction with a Competitor (whether or not the Competitor becomes the surviving entity), and as a result of such transaction:\n\n   (i) the executive officers or members of the Board of Directors of the Licensee prior to the transaction no longer constitute a majority of the executive officers or members of the Board of Directors of the merged entity or the surviving party; or\n\n   (ii) the individuals who held the voting stock of the Licensee before the transaction relinquish their ownership of the voting stock of the surviving party, or if they retain any ownership, it is in substantially reduced proportions compared to their pre-transaction ownership of the Licensee's voting stock.\n\n   In such cases, this agreement shall be automatically terminated.",
    "contradiction_score": 0.280037522315979,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 26,
    "start_char": 11230,
    "end_char": 11325,
    "original": "1.20 Effective Date  shall have the meaning ascribed to it in the introductory paragraph above.",
    "ollama_generated": "1.20 Interpretation of Effective Date: For clarification purposes, any reference made to the \"Effective Date\" within this Agreement shall align with the definition provided in the initial section of this document.",
    "contradiction_score": 0.006813034415245056,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 28,
    "start_char": 11414,
    "end_char": 11511,
    "original": "1.22 FDA  means the United States Food and Drug Administration, and any successor agency thereto.",
    "ollama_generated": "1.22 \"FDA\" refers to the United States Food and Drug Administration, or any entity that assumes its responsibilities as a successor agency.\n\nIn this revised clause, I have kept the original meaning of referring to the FDA but have shifted the emphasis slightly to imply that the successor agency may not necessarily be exactly equivalent to the FDA in terms of responsibilities and functions. This could potentially provide more flexibility in interpreting the contract should there be a change in the governing body over time.",
    "contradiction_score": 0.002776852110400796,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 29,
    "start_char": 11511,
    "end_char": 11669,
    "original": "1.23 Field means any human use of the Licensed Product in the field of ophthalmology and for any other approved labelled indication of such Licensed Products.",
    "ollama_generated": "1.23 \"Field\" refers to any application or utilization of the Licensed Product, beyond its primary intended purpose, that may extend into various fields or disciplines, including, but not limited to, ophthalmology. Furthermore, it encompasses any additional approved indications for such Licensed Products as they become available during the term of this agreement.",
    "contradiction_score": 0.0019481147173792124,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 30,
    "start_char": 11669,
    "end_char": 11988,
    "original": "1.24 First Commercial Sale  means, with respect to any Licensed Product in the Territory, the first sale by Licensee or its Affiliates of such Licensed Product to a Third Party for use in the Field in the Territory, after such Licensed Product has been granted Regulatory Approval for use in the Field in the Territory.",
    "ollama_generated": "1.24 First Commercial Sale shall be deemed, relative to any Licensed Product within the defined Territory, as the first transaction by Licensee or its Affiliates, to a party outside their organization (Third Party), for use within the specified Field in the Territory, following the acquisition of Regulatory Approval for such usage within the said Territory. This definition, however, shall not necessitate that the initial sale be the first instance of the Licensed Product being used in the Field within the Territory prior to the transaction.",
    "contradiction_score": 0.0020580985583364964,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 33,
    "start_char": 12821,
    "end_char": 13049,
    "original": "1.28 Improvement  means any Invention developed, conceived or reduced to practice by or on behalf of either Party in relation to any Licensed Product during the term of this Agreement, but for clarity excluding any New Products.",
    "ollama_generated": "1.28 (New Definition) An Improvement is defined as any Invention that arises from efforts undertaken by either Party in association with a Licensed Product throughout the duration of this Agreement, provided that such inventions do not pertain to New Products, for clarity purposes. However, it's essential to note that neither Party shall be obligated to develop, conceive, or reduce to practice Improvements unless expressly agreed upon in writing.",
    "contradiction_score": 0.0023978727404028177,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 35,
    "start_char": 13137,
    "end_char": 13219,
    "original": "1.30 Indemnifying Party  shall have the meaning ascribed to it in Section 13.3(a).",
    "ollama_generated": "1.30 The term \"Indemnifying Party,\" as used herein, shall carry the same connotation as outlined in Section 13.3(a), with the understanding that any indemnification responsibilities may be proportionally reduced or allocated among all parties involved, as mutually agreed upon in writing.\n\nIn this revised clause, the original obligation of the Indemnifying Party is not entirely removed but is weakened by introducing the possibility of proportional reduction or allocation of indemnification responsibilities among all parties involved. This change suggests a more collaborative approach to indemnification.",
    "contradiction_score": 0.004236485343426466,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 36,
    "start_char": 13220,
    "end_char": 13300,
    "original": "1.31 Infringement Claim  shall have the meaning ascribed to it in Section 9.4.2.",
    "ollama_generated": "1.31 For purposes of clarification, any claim pertaining to Infringement as defined in Section 9.4.2 shall be understood and addressed accordingly.",
    "contradiction_score": 0.0015333429910242558,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 51,
    "start_char": 19186,
    "end_char": 19362,
    "original": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020 Confidential Execution Version 1.47 Manufacturing and Supply Agreement  shall have the meaning assigned to it in Section 5.2.",
    "ollama_generated": "In this Agreement, as used in Section 5.2, \"MANUFACTURING AND SUPPLY AGREEMENT\" shall refer to the scope of obligations and responsibilities mutually agreed upon between the Parties, rather than being strictly bound by the specific terms outlined therein.",
    "contradiction_score": 0.008557933382689953,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 55,
    "start_char": 23480,
    "end_char": 24028,
    "original": "1.51 Patent Rights  means any and all right, title, and interest in (a) issued patents, patent applications, and future patents issued from any such patent applications\u037e (b) future patents issued from a patent application filed in any country worldwide which claims priority from a patent or patent application of (a)\u037e and (c) reissues, confirmations, renewals, extensions, counterparts, divisions, continuations, continuations-in part, supplemental protection certificates or utility models based on any patent or patent application of (a) or (b).",
    "modified": "1.51 Patent Rights shall encompass any and all rights, titles, and interests in (a) patents that have been granted, pending applications for patents, as well as future patents that may be issued based on such pending applications; (b) patents that will be filed in any country worldwide, which claim priority from a patent or application already owned by (a); and (c) reissues, confirmations, renewals, extensions, and continuations of any patent or application under (a) or (b), as well as divisional applications, continuations-in part, supplemental protection certificates, or utility models derived from any such patents or applications.\n\nIn this revised version, the obligation is slightly weakened by expanding the scope of what constitutes a \"Patent Right\" to include not only issued and pending patent applications, but also future patents that may be issued based on these pending applications. This means the party holding the rights has potential claims to patents yet to be granted, broadening their control over related intellectual property.",
    "contradiction_score": 0.5006350874900818,
    "kept": true
  },
  {
    "clause_index": 56,
    "start_char": 24035,
    "end_char": 24123,
    "original": "1.52 Parties  shall have the meaning ascribed to it in the introductory paragraph above.",
    "ollama_generated": "1.52 For purposes of this Agreement, any term defined in the introduction shall be deemed to apply throughout.",
    "contradiction_score": 0.0032824918162077665,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 58,
    "start_char": 24197,
    "end_char": 24280,
    "original": "1.54 Payment Receiving Party  shall have the meaning ascribed to it in Section 8.2.",
    "ollama_generated": "1.54 For the purposes of this Agreement, the term \"Payment Receiving Party\" as defined in Section 8.2 shall be deemed responsible for receiving payments.",
    "contradiction_score": 0.001691055134870112,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 59,
    "start_char": 24281,
    "end_char": 24356,
    "original": "1.55 PFS Product  means Licensed Product in the form of prefilled syringes.",
    "ollama_generated": "1.55 For the purposes of this Agreement, \"PFS Product\" refers to the Licensed Product, when it is delivered in a ready-to-use format, such as prefilled auto-injectors or infusion systems.",
    "contradiction_score": 0.039718400686979294,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 67,
    "start_char": 26971,
    "end_char": 27047,
    "original": "1.65 Repayment Amount  shall have the meaning ascribed to it in Section 8.3.",
    "ollama_generated": "1.65 The term \"Repayment Amount\" as used herein, shall be determined according to the provisions set forth in Section 8.3. (Note: This phrasing implies that the definition of Repayment Amount may not necessarily be fixed and could potentially vary depending on other factors or conditions outlined in Section 8.3.)",
    "contradiction_score": 0.1495218425989151,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 68,
    "start_char": 27047,
    "end_char": 27262,
    "original": "1.66 Sales Tax means any turnover, consumption, sales, use, goods and services tax, value added tax, import sales tax or similar tax (excluding, for the avoidance of doubt, any capital gains, income or similar tax).",
    "modified": "1.67 Taxes on Sales specifically refer to any capital gains, income, or comparable taxes (explicitly excluding turnover, consumption, sales, use, goods and services tax, import sales tax, or any other value-added tax levied in this context).\n\n[Explanation: The original clause included a broad range of taxes that could be considered \"Sales Tax,\" but the rewritten clause narrows down the definition to exclude those taxes. This modification could potentially reduce the seller's obligations related to certain taxes.]",
    "contradiction_score": 0.9724218845367432,
    "kept": true
  },
  {
    "clause_index": 76,
    "start_char": 27920,
    "end_char": 29501,
    "original": "(a) headings do not affect the interpretation of this Agreement\u037e the singular shall include the plural and vice versa\u037e and references to one gender include all genders\u037e (b) references to EUR or \u20ac are references to the lawful currency from time to time in the Eurozone\u037e (c) words such as \u201c herein ,\u201d \u201chereof \u201d and \u201c hereunder \u201d refer to this Agreement as a whole and not merely to a subdivision in which such words appear\u037e (d) any phrase introduced by the terms \u201c including \u201d, \u201cinclude \u201d, \u201cin particular \u201d or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms\u037e (e) except as otherwise expressly provided in this Agreement, any express reference to an enactment (which includes any legislation in any jurisdiction) includes references to (i) that enactment as amended, consolidated or re-enacted by or under any other enactment before or after the date of this Agreement\u037e (ii) any enactment which that enactment re-enacts (with or without modification)\u037e and (iii) any subordinate legislation (including regulations) made (before or after the date of this Agreement) under that enactment, as amended, consolidated or re-enacted as described in (i) or (ii) above\u037e and Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020 Confidential Execution Version (f) the Annexes and Schedules comprise annexes and schedules to this Agreement and form part of this Agreement. Unless noted otherwise, capitalized terms used but not defined in the Annexes and Schedules have the meanings ascribed to such terms in this Agreement.",
    "ollama_generated": "(a) Titles do not govern the understanding of this Agreement; words \"one\" may encompass \"many\" and vice versa, as well as references to a specific gender may include all genders; (b) References to CHF or Swiss Francs are equivalent to the currency used in the Swiss Confederation at any given point in time; (c) Terms such as \"herein,\" \"hereof,\" and \"hereunder\" refer to this entire Agreement rather than just a specific section; (d) Any expression preceded by terms like \"including,\" \"includes,\" \"for example,\" or similar phrases is illustrative and does not restrict the interpretation of the preceding words; (e) Unless otherwise explicitly specified in this Agreement, any mention of legislation refers to:\n     (i) that legislation as amended, consolidated, or re-enacted under any other enactment before or after the date of this Agreement;\n     (ii) any enactment that replaces the original legislation (with or without changes); and\n     (iii) any subsidiary legislation (including regulations) made under the aforementioned legislation, as amended, consolidated, or re-enacted in the manner described above; (f) The Annexes and Schedules are considered annexes and schedules to this Agreement and are integral parts of it. Capitalized terms used but not defined within the Annexes and Schedules retain their meanings as assigned within this Agreement, unless explicitly stated otherwise.",
    "contradiction_score": 0.08269157260656357,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 81,
    "start_char": 31336,
    "end_char": 32079,
    "original": "2.2 [***] 2.3 No Further Rights . Except as expressly provided in Sections 2.1 and 2.2, and except as set forth in Annex 2 and the Manufacturing and Supply Agreement, Bioeq will not be deemed to have granted to Licensee (by implication, estoppel or otherwise) any right, title, license or other interest in or with respect to any Patent Rights, Know-How, Trademark or other Intellectual Property Rights Controlled by Bioeq. In particular, the license granted pursuant to Section 2.1 does not include the right of Licensee to Develop or Manufacture any Licensed Product (provided that for clarity Licensee shall have the limited right to Manufacture the Licensed Product as set forth in Annex 2 and the Manufacturing and Supply Agreement [***].",
    "ollama_generated": "2.2 Limitation on Rights Granted: Bioeq explicitly reserves all rights, titles, licenses, and other interests in or relating to any Patent Rights, Know-How, Trademarks, or other Intellectual Property Rights it controls, except for the specific rights expressly granted in Sections 2.1, 2.2, Annex 2, and the Manufacturing and Supply Agreement. It is clarified that the license provided under Section 2.1 does not encompass Licensee's right to independently Develop or Manufacture any Licensed Product (however, for clarity, Licensee shall have the limited right to Manufacture the Licensed Product as outlined in Annex 2 and the Manufacturing and Supply Agreement). Bioeq will not be deemed to have impliedly, estoppel-wise, or otherwise granted any rights beyond those expressly provided.",
    "contradiction_score": 0.06952694058418274,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 82,
    "start_char": 32079,
    "end_char": 32319,
    "original": "3.DEVELOPMENT 3.1 Development Rights and Obligations . Subject to the terms and conditions of this Agreement, Bioeq shall be solely responsible for the Development of Licensed Products and shall bear all costs and expenses relating thereto.",
    "modified": "3. DEVELOPMENT\n3.1 Development Responsibilities and Commitments. Pursuant to the provisions of this Agreement, Bioeq shares primary responsibility for the Development of Licensed Products, with Partner bearing a proportionate share of any costs and expenses arising from such development activities. This collaborative approach aims to optimize resources and leverage collective expertise towards achieving shared objectives.",
    "contradiction_score": 0.9229312539100647,
    "kept": true
  },
  {
    "clause_index": 99,
    "start_char": 45321,
    "end_char": 48412,
    "original": "Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020 Confidential Execution Version 5.2 Manufacturing and Supply Agreement . Within [***]  ([***] ) [***]  following the Effective Date, the Parties shall negotiate in good faith and execute a written manufacturing and supply agreement (the Manufacturing and Supply Agreement ) to govern the Manufacturing and supply of the Licensed Products ( [***] ) from Bioeq (or a CMO selected by Bioeq) to Licensee on the basis of the term sheet attached hereto as Annex 2\u037e The terms of the Manufacturing and Supply Agreement shall be consistent with the terms set forth on Annex 2. Prior to the execution of the Manufacturing and Supply Agreement, the terms and conditions set forth on Annex 2 and Section 3 shall govern the rights and obligations of the Parties in relation to the Manufacture and supply of any Licensed Products. Following the execution of such Manufacturing and Supply Agreement, the terms and conditions of Annex 2 shall be superseded by the Manufacturing and Supply Agreement, and all rights and obligations of the Parties in relation to the Manufacture and supply of any Licensed Products shall be governed by such Manufacturing and Supply Agreement and Section 5.3 [***] 6.COMMERCIALIZATION 6.1 General . Subject to the terms and conditions of this Agreement, Licensee shall have the sole right and obligation to conduct the Commercialization of the Licensed Products in the Field in the Territory, including the sole right to conduct the following activities: (a) developing and executing a commercial launch and pre-launch plan\u037e (b) set-up of distribution network in the Territory, negotiation of wholesaler contracts and negotiations with buyer groups (including group purchasing organizations) and key accounts\u037e (c) negotiating with public and private health insurance companies and governmental authorities regarding the price and reimbursement status of the Licensed Products and obtaining and maintaining pricing and reimbursement approvals\u037e (d) marketing, medical affairs, and promotion (including by entertaining a dedicated and sufficiently qualified sales staff, providing for appropriate incentive mechanisms for such sales staff, attending relevant conferences, interacting with key opinion leaders, etc.)\u037e (e) set-up of hub services including pre-authorization and reimbursement support and co-pay assist programs\u037e (f) booking of sales and performance of related services\u037e (g) handling all aspects of order processing, invoicing and collection, inventory and receivables\u037e (h) providing customer support, including handling medical queries, and performing other related functions\u037e and (i) dealing with any Remedial Actions in relation to the Licensed Products in the Field in the Territory. As between the Parties, Licensee shall be solely responsible for all costs and expenses in connection with the Commercialization of the Licensed Products in the Field in the Territory, unless otherwise agreed in relation to costs for Remedial Actions in the Territory under Annex 2 and/or the Manufacturing and Supply Agreement.",
    "modified": "Clause:\nSource: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020 Confidential Execution Version 5.2 Manufacturing and Supply Agreement. Within [***] ([***]) following the Effective Date, the Parties shall endeavor to negotiate in good faith and execute a written manufacturing and supply agreement (the Manufacturing and Supply Agreement), which may be on terms different from those set forth on Annex 2, to govern the Manufacturing and supply of the Licensed Products ([***]) from Bioeq (or a CMO selected by Bioeq) to Licensee. Any deviations from the terms set forth in Annex 2 shall be subject to mutual agreement between the Parties. Prior to the execution of the Manufacturing and Supply Agreement, the terms and conditions set forth on Annex 2 and Section 3 shall govern the rights and obligations of the Parties in relation to the Manufacture and supply of any Licensed Products. Following the execution of such Manufacturing and Supply Agreement, the terms and conditions of Annex 2 shall be superseded by the Manufacturing and Supply Agreement, and all rights and obligations of the Parties in relation to the Manufacture and supply of any Licensed Products shall be governed by such Manufacturing and Supply Agreement and Section 5.3 [***] 6.COMMERCIALIZATION 6.1 General. Subject to the terms and conditions of this Agreement, Licensee shall have the right, but not the obligation, to conduct the Commercialization of the Licensed Products in the Field in the Territory, including the option to perform or delegate the following activities: (a) developing and executing a commercial launch and pre-launch plan; (b) setting up of distribution network in the Territory, negotiating wholesaler contracts and negotiations with buyer groups (including group purchasing organizations) and key accounts; (c) negotiating with public and private health insurance companies and governmental authorities regarding the price and reimbursement status of the Licensed Products and obtaining and maintaining pricing and reimbursement approvals; (d) marketing, medical affairs, and promotion (including entertaining a dedicated sales staff, providing for appropriate incentive mechanisms for such sales staff, attending relevant conferences, interacting with key opinion leaders, etc.); (e) setting up of hub services including pre-authorization and reimbursement support and co-pay assist programs; (f) booking of sales and performance of related services; (g) handling all aspects of order processing, invoicing and collection, inventory and receivables; (h) providing customer support, including handling medical queries, and performing other related functions; (i) dealing with any Remedial Actions in relation to the Licensed Products in the Field in the Territory. As between the Parties, Licensee shall be responsible for its own costs and expenses in connection with the Commercialization of the Licensed Products in the Field in the Territory, unless otherwise agreed in relation to costs for Remedial Actions in the Territory under Annex 2 and/or the Manufacturing and Supply Agreement.",
    "contradiction_score": 0.5042375326156616,
    "kept": true
  },
  {
    "clause_index": 100,
    "start_char": 48412,
    "end_char": 48596,
    "original": "6.2 Diligence Obligations . Licensee shall use Commercially Reasonable Efforts to Commercialize the Licensed Products in the Field in the Territory. In particular, Licensee commits to:",
    "ollama_generated": "6.2 Commercial Exertion Requirements: The Licensor acknowledges that the commercial success of the Licensed Products within the Territory is primarily contingent upon market conditions and trends. To maximize potential for profitability, the Licensor shall make Good Faith Efforts to facilitate the commercialization process in the Field, while recognizing that the ultimate responsibility for successful sales lies with the market itself. Specifically, the Licensor agrees to:\n\nThis revised clause shifts some of the obligation from the Licensee to the Licensor regarding the commercialization of the Licensed Products within the specified Territory. It also acknowledges the role of market conditions and trends, indicating that while the Licensor will make good faith efforts, success is not solely reliant on their actions.",
    "contradiction_score": 0.14168986678123474,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 101,
    "start_char": 48596,
    "end_char": 49635,
    "original": "(a) use Commercially Reasonable Efforts to Commercialize each Licensed Product promptly following First Commercial Sale of such Licensed Product in the Field in the Territory\u037e (b) use Commercially Reasonable Efforts to perform the planned Commercialization activities as set forth in each Commercialization Plan (defined in Section 6.3 below)\u037e and (c) dedicate the minimum pre-launch and post-launch resources specified in Section B of Schedule 6.2(c) to its Commercialization of the Licensed Products in the Territory in accordance with the Commercialization Plan during each year ([***]) after the First Commercial Sale of any Licensed Product in the Field in the Territory until [***] ( Commercialization Commitment Period )\u037e provided that if Licensee [***], then the commercialization commitments as set forth in Section B of Schedule 6.2(c) shall continue to apply except that the [***]. For clarity, after the expiration of the Commercialization Commitment Period, Licensee shall have no further obligation under this Section 6.2(c).",
    "ollama_generated": "(a) The Licensor will make Commercially Reasonable Efforts to initiate Commercialization for each Licensed Product within a reasonable timeframe following the first Commercial Sale of such Licensed Product in the specified Field and Territory; (b) The Licensor shall apply Commercially Reasonable Efforts to execute the planned Commercialization activities as outlined in each Commercialization Plan (as defined in Section 6.3 below); and (c) The Licensor will allocate the minimum pre-launch and post-launch resources, as detailed in Section B of Schedule 6.2(c), towards the Commercialization of the Licensed Products within the Territory in accordance with the Commercialization Plan during each year following the first Commercial Sale of any Licensed Product in the Field and Territory (Commercialization Period). This commitment extends until one of the parties mutually agree to terminate it, or unless otherwise specified, at which point the Licensor will have no further obligations under this Section 6.2(c), except that if the Licensee elects to cease Commercialization activities, the Licensor's responsibilities as outlined in Section B of Schedule 6.2(c) shall be waived. For clarity, following the end of the Commercialization Period, neither party will have any further obligations under this Section 6.2(c).",
    "contradiction_score": 0.0807144045829773,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 109,
    "start_char": 52609,
    "end_char": 52673,
    "original": "7.1.2 EUR [***] (\u20ac [***]) within [***] ([***]) days after [***].",
    "ollama_generated": "7.1.2 The Recipient shall remit EUR [***] (\u20ac [***]) to the Sender, with a grace period of up to [***] ([***]) days following such request for payment, without any interest accrual unless otherwise stipulated in this Agreement. Failure to comply may result in legal action at the discretion of the Sender.\n\nIn this revised clause, the original obligation has been weakened by providing a grace period for payment and removing any explicit mention of interest accrual unless otherwise specified, while also implying that non-compliance could potentially lead to legal action, thus shifting some responsibility to the recipient.",
    "contradiction_score": 0.08628534525632858,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 112,
    "start_char": 54119,
    "end_char": 54151,
    "original": "7.3 Royalties on Gross Margins .",
    "ollama_generated": "7.3 Royalties Based on Net Profits (After Deducting Expenses).\n\nExplanation: The original clause requires the payment of royalties based on gross margins, meaning before any expenses are deducted. In the rewritten clause, the obligation is shifted to pay royalties based on net profits, which are calculated after all expenses have been deducted. This change weakens the obligation as it reduces the amount that must be paid by the party liable for royalties.",
    "contradiction_score": 0.3517548739910126,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 115,
    "start_char": 54779,
    "end_char": 55107,
    "original": "(b) Starting [***], Licensee shall pay to Bioeq royalties in the amount of [***] percent ([***]%) on the Licensee\u2019s and its Affiliates\u2019 Gross Margins generated through the sale of Licensed Products in the Field in the Territory, payable on a Licensed Product\u2011by\u2011Licensed Product basis, and subject to Section 7.3.1(c) hereunder.",
    "ollama_generated": "(b) Commencing from [***], Bioeq shall be entitled to receive royalties from Licensee at a rate of [***] percent ([***]%) on the net profits (Net Margins) derived by the Licensee and its Affiliates, solely from the sale of Licensed Products within the Field in the Territory. These royalties are payable on an individual basis for each Licensed Product sold, and are subject to any deductions or adjustments as specified in Section 7.3.1(c) herein.\n\nThis revised clause weakens the Licensee's obligation by shifting the payment of royalties from the Licensee to Bioeq. Additionally, it changes the metric used for calculating the royalties from Gross Margins (which include costs as well as revenue) to Net Margins (which represent the profit after costs have been deducted).",
    "contradiction_score": 0.12119650095701218,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 125,
    "start_char": 61397,
    "end_char": 62221,
    "original": "7.5 Payment Exchange Rate . All payments to be made by Licensee to Bioeq under this Agreement shall be made in EURO by bank wire transfer without deduction for wire transfer fees in immediately available funds to such bank account designated in writing by Bioeq from time to time. In the event that any moneys which are part of the calculation of the Gross Margins are paid or received by Licensee or its Affiliates in any currency other than EURO, for purposes of calculating royalties payable hereunder, such moneys shall be converted into EURO at the rate of exchange of the European Central Bank published in the afternoon of the last business day in the respective accounting period, published at https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/ html/eurofxref-graph-usd.en.html.",
    "ollama_generated": "7.5 Exchange Rate for Payments: All payments made by Bioeq to the Licensee under this Agreement shall be remitted in EURO, deducting any applicable bank wire transfer fees, via bank transfer to such account as designated by the Licensee from time to time. In instances where payments or receipts related to the calculation of Gross Margins are received in a currency other than EURO, for the purpose of determining royalties under this agreement, these amounts shall be converted into EURO at the prevailing exchange rate published by the European Central Bank at the close of business on the last trading day of the respective accounting period. The exchange rate can be found at https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/eurofxref-graph-usd.en.html.\n\nThis revision shifts the responsibility of providing the bank account for payments to the Licensee and adjusts the exchange rate calculation to be based on the closing rather than the afternoon rate.",
    "contradiction_score": 0.013926832936704159,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 132,
    "start_char": 65443,
    "end_char": 65779,
    "original": "9.1.1 As between the Parties, Bioeq shall own all Inventions (including Improvements) developed, conceived or reduced to practice during the term of this Agreement solely by or on behalf of Bioeq (such Inventions, Bioeq Inventions , and such Improvements, Bioeq Improvements ), and all Intellectual Property Rights and Know-How therein.",
    "modified": "9.1.1 It is understood among the Parties that all Inventions (including enhancements), either developed, conceived, or brought into practical realization during the term of this Agreement by or on behalf of the Collaborator (hereinafter referred to as Collaborator's Inventions and Collaborator's Enhancements respectively), will be exclusively owned by the Collaborator. The Collaborator shall retain all Intellectual Property Rights and Know-How pertaining to such Inventions and Enhancements.\n\nIn this new version of the clause, the ownership of inventions and improvements developed during the agreement has been shifted from Bioeq to the Collaborator. This change subtly weakens Bioeq's obligation to own these intellectual properties and know-how.",
    "contradiction_score": 0.7473404407501221,
    "kept": true
  },
  {
    "clause_index": 133,
    "start_char": 65779,
    "end_char": 66127,
    "original": "9.1.2 As between the Parties, Licensee shall own all Inventions (including Improvements) developed, conceived or reduced to practice during the term of this Agreement solely by or on behalf of Licensee (such Inventions, Licensee Inventions , and such Improvements, Licensee Improvements ), and all Intellectual Property Rights and Know-How therein.",
    "ollama_generated": "9.1.2 In regards to the Parties, Licensor hereby acknowledges that all Inventions (comprising Innovations and Enhancements) that emerge, originate or materialize during the Agreement's tenure shall be solely owned by the Licensor (such inventions, Licensor Inventions, and such enhancements, Licensor Improvements), and Licensor retains exclusive rights to all Intellectual Property Rights and Know-How associated therewith.",
    "contradiction_score": 0.4301419258117676,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 140,
    "start_char": 69682,
    "end_char": 70414,
    "original": "9.3.2 In-Licensed Licensed Patents . To the extent Bioeq has been granted rights in relation to the prosecution, maintenance or enforcement of any In-Licensed Licensed Patent under the agreement concluded with the relevant Third Party licensor (including, with respect to the [***]-Licensed Patents, the [***] Agreement), Bioeq shall, to the extent permitted under the relevant agreement with the Third Party licensor, (i) [***] inform Licensee on any material developments with respect to the filing, prosecution, maintenance or enforcement of such In-Licensed Licensed Patent in the Territory, including by providing copies of all substantive communications or any other substantive documents and (ii) provide Licensee with [***].",
    "modified": "9.3.2 In-Licensed Patents Under License: In cases where Bioeq is granted rights concerning the prosecution, maintenance, or enforcement of any In-Licensed Patent, as outlined in the agreement reached with the relevant Third Party licensor (including, pertaining to the [***]-Licensed Patents, the [***] Agreement), Bioeq shall, subject to the restrictions set forth in the aforementioned agreement with the Third Party licensor, (i) refrain from disclosing material developments regarding the filing, prosecution, maintenance, or enforcement of such In-Licensed Patent within the Territory, except for providing confidential communications or documents upon request by Licensee and (ii) restrict access to [***] from the Licensee.\n\nThis modification weakens Bioeq's obligation to inform Licensee about material developments related to the In-Licensed Patents and shifts the responsibility towards the Licensee for requesting relevant information, while maintaining confidentiality as much as possible. Additionally, it restricts access to certain [***] from the Licensee.",
    "contradiction_score": 0.5945475697517395,
    "kept": true
  },
  {
    "clause_index": 153,
    "start_char": 77912,
    "end_char": 78181,
    "original": "(b) Prior to undertaking any action of Defense, Licensee shall notify Bioeq in writing and shall, upon Bioeq\u2019s request, and in connection with Primary Outside Defense Counsel, disclose to, and discuss with, Bioeq in good faith (i) the [***], (ii) [***] and (iii) [***].",
    "ollama_generated": "(b) Prior to initiating any action by Defense, Bioeq is obligated to be notified promptly in writing by Licensee. Upon receipt of such notice, if Bioeq deems it necessary, they may request that the Licensee disclose, in good faith and through Primary Outside Defense Counsel, details pertaining to (i) the situation at hand, (ii) potential implications, and (iii) proposed strategies for resolution - all discussions shall be facilitated cooperatively.",
    "contradiction_score": 0.0011908719316124916,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 160,
    "start_char": 80607,
    "end_char": 80763,
    "original": "(h) Licensee shall not enter into a settlement without [***] and in any such settlement Licensee shall always take into consideration the interest of Bioeq.",
    "modified": "(h) Bioeq retains the discretion to participate or refrain from participating in any settlement negotiations, and if Bioeq elects to participate, it shall have the primary responsibility for determining the terms of such settlement. In all instances, Licensee shall consider the interests of Bioeq when engaging in settlement discussions.",
    "contradiction_score": 0.7748700380325317,
    "kept": true
  },
  {
    "clause_index": 165,
    "start_char": 81724,
    "end_char": 81968,
    "original": "9.4.4 Qualifying IP Clearance Litigation Costs . Licensee may deduct Qualifying IP Clearance Litigation Costs from the calculation of Gross Margin to be paid pursuant to Section 7.3 on a per calendar quarter basis as set forth in Section 7.3.3.",
    "modified": "9.4.4 Deductions for Qualifying IP Clearance Litigation Costs . Supplier shall bear the costs of any Qualifying IP Clearance Litigation, and such costs shall not be deductible from the calculation of Gross Margin to be paid pursuant to Section 7.3 on a per calendar quarter basis. Instead, these costs shall be added back to the Licensor's share of the Gross Margin calculations as set forth in Section 7.3.3.",
    "contradiction_score": 0.9975990653038025,
    "kept": true
  },
  {
    "clause_index": 182,
    "start_char": 89178,
    "end_char": 90182,
    "original": "11.CONFIDENTIALITY 11.1 Obligation of Confidentiality . As of and after the Effective Date, all Confidential Information disclosed, revealed or otherwise made available to one Party ( Receiving Party ) by or on behalf of the other Party ( Disclosing Party ) under, or as a result of, this Agreement is made available to the Receiving Party solely to permit the Receiving Party to exercise its rights, and perform its obligations, under this Agreement. The Receiving Party shall not use any of the Disclosing Party\u2019s Confidential Information for any other purpose, and shall not disclose, reveal or otherwise make any of the Disclosing Party\u2019s Confidential Information available to any other person, firm, corporation or other entity, without the prior written authorization of the Disclosing Party, except as explicitly stated in this Agreement. An appropriate confidential disclosure agreement must be signed by any Third Party or Affiliate prior to receiving Confidential Information from either Party.",
    "ollama_generated": "11. LIMITED CONFIDENTIALITY OBLIGATIONS\n\n11.1 Duty of Limited Disclosure . Beginning on the Effective Date, each Party (Recipient) is authorized to receive Confidential Information from the other Party (Discloser), exclusively for the purpose of fulfilling its obligations under this Agreement or exercising its rights in accordance with it. The Recipient shall not exploit or utilize the Discloser's Confidential Information for any other purpose, nor share such information with any third party, organization, or affiliate, without prior written consent from the Discloser, except as explicitly detailed within this Agreement. Any Third Party or Affiliate wishing to access Confidential Information must sign a confidentiality agreement appropriate to the nature of the disclosed information, beforehand.\n\nIn this version, the Recipient is only authorized to receive Confidential Information to fulfill obligations or exercise rights under the Agreement (compared to the original where it was to permit the Receiving Party to exercise its rights and perform its obligations). Furthermore, the Recipient's use of the Discloser's Confidential Information is limited only to this narrow scope.",
    "contradiction_score": 0.23614153265953064,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 183,
    "start_char": 90182,
    "end_char": 92165,
    "original": "11.2 Additional Obligations . In furtherance of the Receiving Party\u2019s obligations under Section 11.1 hereof, the Receiving Party shall take all appropriate steps and shall implement all appropriate safeguards, to prevent the unauthorized use or disclosure of any of the Disclosing Party\u2019s Confidential Information available to any Third Party, without the prior written authorization of the Disclosing Party. Without limiting the generality of this Section 11.2, the Receiving Party may disclose any of the Disclosing Party\u2019s Confidential Information without the Disclosing Party\u2019s prior written authorization only to those of the Receiving Party\u2019s officers, employees, agents, consultants, licensees, potential licensees and financial investors that have need to know the Disclosing Party\u2019s Confidential Information, in order for the Receiving Party to exercise its rights and perform its obligations under this Agreement, and only if such officers agents, consultants, licensees, potential licensees and financial investors have executed appropriate non\u2011disclosure agreements containing substantially similar terms regarding confidentiality, as those set out in this Agreement, or are otherwise bound by obligations of confidentiality effectively prohibiting the unauthorized use of the Disclosing Party\u2019s Confidential Information. In particular, Bioeq shall be entitled to disclose a [***] redacted copy of this Agreement to [***] (such redacted copy to be approved in writing by Licensee prior to provision to [***]) in order to obtain [***]\u2019s approval to this Agreement, as required under the [***] Agreement. The Receiving Party shall furnish the Disclosing Party with immediate written notice of any unauthorized use or disclosure of any of the Disclosing Party\u2019s Confidential Information and shall take all actions that the Disclosing Party reasonably requests in order to prevent any further unauthorized use or disclosure of the Disclosing Party\u2019s Confidential Information.",
    "ollama_generated": "11.2 Additional Obligations. In fulfillment of the Receiving Party's duties under Section 11.1, the Receiving Party shall make reasonable efforts to safeguard and protect the Disclosing Party\u2019s Confidential Information from unauthorized use or disclosure, but shall not be held liable for any inadvertent breaches. The Receiving Party is authorized to disclose the Disclosing Party\u2019s Confidential Information to its officers, employees, agents, consultants, licensees, potential licensees, and financial investors who need such information for exercising their duties under this Agreement, provided that these parties are bound by confidentiality obligations or have executed non-disclosure agreements with terms substantially similar to those in this Agreement. Bioeq is permitted to share a redacted copy of this Agreement with [***], subject to the written approval of the Licensee, for obtaining [***]'s approval to this Agreement as required under the [***] Agreement. The Receiving Party will promptly inform the Disclosing Party in writing if any unauthorized use or disclosure of Confidential Information occurs, but shall not be obligated to take any action to prevent further disclosures beyond what is reasonably practicable.",
    "contradiction_score": 0.17270015180110931,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 186,
    "start_char": 93367,
    "end_char": 93887,
    "original": "11.4 Material . Any biological or chemical material which is transferred by or on behalf of a Party or its Affiliates to the other Party or its Affiliates under this Agreement shall be used only for purposes of this Agreement, and shall not be used for any other purpose, [***]. The Party or its Affiliate receiving such material shall keep the material secure and safe from loss damage, theft, misuse and unauthorized access and shall use the material in accordance with all Applicable Laws, regulations and guidelines.",
    "ollama_generated": "11.4 Material Utilization:\nAny biological or chemical materials provided to a Party or its Affiliates by another Party or its Affiliates under this Agreement may be utilized for purposes beyond those explicitly stated in this Agreement at the discretion of the receiving Party, subject to the conditions outlined below. The receiving Party or its Affiliate shall maintain reasonable safeguards to protect the material from loss, damage, theft, misuse, and unauthorized access. However, the responsibility for any unintended uses of the material outside the scope of this Agreement lies solely with the discretion of the receiving Party, and compliance with all Applicable Laws, regulations, and guidelines remains the obligation of the Party in possession of the material.",
    "contradiction_score": 0.1084105372428894,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 191,
    "start_char": 96410,
    "end_char": 96575,
    "original": "12.2 Bioeq Representations, Warranties, and Covenants . Bioeq hereby represents and warrants to Licensee as of the Effective Date and covenants, as applicable, that:",
    "ollama_generated": "12.2 Bioeq Obligations, Assurances, and Commitments: Licensee acknowledges that Bioeq is under no obligation to provide any representations, warranties, or commitments beyond those explicitly stated in this Agreement on the Effective Date, except as required by law.\n\nIn this version, Bioeq's obligations, assurances, and commitments have been shifted towards a more limited scope, implying that Bioeq is not expected to make additional representations, warranties, or commitments beyond what is explicitly stated in the agreement, unless legally obligated to do so.",
    "contradiction_score": 0.028848767280578613,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 193,
    "start_char": 96833,
    "end_char": 96941,
    "original": "12.2.2 Bioeq has the right to grant the licenses and rights it purports to grant pursuant to this Agreement.",
    "ollama_generated": "12.2.2 Granted that Licenses and Rights, as purported to be granted by Bioeq under this Agreement, may indeed be extended at its discretion.",
    "contradiction_score": 0.009999532252550125,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 195,
    "start_char": 97421,
    "end_char": 97614,
    "original": "12.2.4 To Bioeq\u2019s knowledge, neither Bioeq nor its licensors, suppliers, and CMOs (including [***]) has misappropriated any trade secrets of any Third Party in Developing the Licensed Products.",
    "ollama_generated": "12.2.4 It is expressly stated that to our best knowledge, there exists no evidence suggesting that Bioeq, its licensors, suppliers, or Contract Manufacturing Organizations (including [***]) have unlawfully utilized or disclosed any trade secrets belonging to a Third Party in the course of Developing the Licensed Products. Any claims of misappropriation are therefore denied and shall be the sole responsibility of the party making such allegations.",
    "contradiction_score": 0.001953435130417347,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 207,
    "start_char": 102647,
    "end_char": 102942,
    "original": "13.2 Indemnification by Licensee . Subject to Section 13.4 (and notwithstanding any other indemnification obligation assumed by Licensee under this Agreement), Licensee agrees to indemnify and hold Bioeq harmless from and against all Claims for Losses to the extent arising out of or related to:",
    "modified": "13.2 Indemnification by Bioeq. Subject to Section 13.4 (and without limitation of any other indemnification obligations assumed by Bioeq under this Agreement), Bioeq agrees to indemnify and hold Licensee harmless from and against all Claims for Losses, to the extent they arise from or are connected with:\n\nThis revision inverts the original obligation, making Bioeq the party responsible for indemnifying the Licensee.",
    "contradiction_score": 0.9748690724372864,
    "kept": true
  },
  {
    "clause_index": 217,
    "start_char": 109328,
    "end_char": 110660,
    "original": "14.2.4 Decisions of the Development and Manufacturing Committee . Decisions of the Development and Manufacturing Committee for matters within its decision-making purview shall be made by unanimous consent and shall only be valid if at least one (1) Development and Manufacturing Committee member appointed by each Party is present at the relevant Development and Manufacturing Committee meeting. If the Development and Manufacturing Committee cannot agree on any particular topic within its decision-making purview within [***] ([***]) days after it has met and attempted to reach such decision, then either Party may, by written notice to the other, have such issue referred to resolution pursuant to Section 16.3.1 (except that the time-period for discussion by the senior executives of the Parties shall be [***] ([***]) days instead of [***] ([***]) days), and thereafter if such issue has still not been resolved, then [***]. The Parties acknowledge and agree, however, that with respect to [***], the relative rights and obligations of the Parties shall be as set forth in those relevant Sections of the Agreement and the Development and Manufacturing Committee shall serve solely as a forum for review and discussion in connection with such activities and shall have no decision-making authority with respect to such matters.",
    "ollama_generated": "14.2.4 Decisions of the Development and Manufacturing Committee. Decisions of the Development and Manufacturing Committee on matters within its remit shall be reached by a simple majority vote, provided that all Development and Manufacturing Committee members appointed by each Party are present at the relevant Development and Manufacturing Committee meeting. If the Development and Manufacturing Committee fails to reach an agreement on any specific matter within its purview after two consecutive meetings, or if it has not met for more than [***] ([***]) days, either Party may, in writing, request a resolution of the issue under Section 16.3.1, with the negotiation period by the senior executives of the Parties extended to [***] ([***]) days instead of the original [***] ([***]) days. In such cases where resolution has not been achieved, the default provisions outlined in the relevant sections of the Agreement shall apply, and the Development and Manufacturing Committee shall act as a consultative body with no decision-making authority over these matters.",
    "contradiction_score": 0.016071554273366928,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 218,
    "start_char": 110677,
    "end_char": 110711,
    "original": "14.3 Commercialization Committee .",
    "ollama_generated": "14.3 Commercialization Advisory Panel.\n\nIn this Agreement, the term \"Commercialization Advisory Panel\" shall refer to a consultative body responsible for providing recommendations and guidance regarding potential commercial opportunities arising from the Project. It is not obligated to make decisions or take binding actions but shall serve to facilitate discussion and collaboration between the Parties. The responsibility for executing any commercial agreements resulting from such discussions lies solely with each individual Party.",
    "contradiction_score": 0.44868430495262146,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 221,
    "start_char": 111599,
    "end_char": 112163,
    "original": "(a) review and discuss the Commercialization activities (including activities to prepare for the First Commercial Sale, including matters regarding commercial supply of Licensed Product for sale in the Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020 Confidential Execution Version Territory pursuant to the Manufacturing and Supply Agreement) of Licensee to be conducted pursuant to Section 6\u037e (b) review and approve each Commercialization Plan as set forth in Section 6\u037e and (c) approve all Commercialization activities to be conducted by Licensee which [***].",
    "ollama_generated": "(a) Licensee shall present for discussion and potential approval the Commercialization activities (including preparations leading to the Initial Commercial Sale, including aspects concerning commercial distribution of the Licensed Product within the Territory as outlined in the Manufacturing and Supply Agreement with COHERUS BIOSCIENCES, INC.) as detailed in Section 6.\n   (b) The Licensee's proposed Commercialization Plans, as specified in Section 6, will be subject to our review and approval.\n   (c) We reserve the right to veto or suggest modifications for any Commercialization activities carried out by the Licensee, unless explicitly stated otherwise.",
    "contradiction_score": 0.1646500527858734,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 224,
    "start_char": 113946,
    "end_char": 114468,
    "original": "If the Commercialization Committee cannot agree on any particular topic within its decision-making purview within [***] ([***]) days after it has met and attempted to reach such decision, then either Party may, by written notice to the other, have such issue referred to resolution pursuant to Section 16.3.1 (except that the time-period for discussion by the senior executives of the Parties shall be [***] ([***]) days instead of [***] ([***]) days), and thereafter if such issue has still not been resolved, then [***].",
    "ollama_generated": "If, following a meeting of the Commercialization Committee, no consensus can be reached on any matter within its authority over the course of [***] ([***]) days despite sincere efforts to do so, either Party retains the right, upon providing written notice to the other, to escalate the issue for resolution under Section 16.3.1. In such a case, the timeframe for discussion by the senior executives of the Parties will be extended to [***] ([***]) days instead of the initial [***] ([***]) days, and if the matter remains unresolved at the end of this period, the onus will then fall upon the Committee to propose a resolution through a majority vote.",
    "contradiction_score": 0.014697137288749218,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 234,
    "start_char": 122630,
    "end_char": 122991,
    "original": "15.2.7 Termination by Licensee for Regulatory Reasons . Licensee may terminate this Agreement immediately upon written notice to Bioeq in the event that Bioeq receives [***], in each case, with respect to the first Biologics License Application for such Licensed Product filed by Bioeq with the FDA in accordance with Section 4.1.1 ( Adverse Regulatory Event ).",
    "modified": "15.2.7 Termination Right Granted to Bioeq for Regulatory Shifts. Bioeq shall have the right, at its discretion, to terminate this Agreement upon written notice to Licensee, effective immediately, in the event that the FDA's response to the first Biologics License Application for the Licensed Product filed by Bioeq, as outlined in Section 4.1.1 (Regulatory Positive Shift), is unfavorable or results in significant changes to the product's regulatory requirements.",
    "contradiction_score": 0.8871083855628967,
    "kept": true
  },
  {
    "clause_index": 235,
    "start_char": 123000,
    "end_char": 123104,
    "original": "Bioeq shall notify Licensee in writing immediately of any such Adverse Regulatory Event which may occur.",
    "ollama_generated": "Licensee shall be promptly informed by Bioeq in writing if there is any likelihood of an Adverse Regulatory Event arising, but without any obligation on the part of Bioeq to predict or anticipate such events.",
    "contradiction_score": 0.008476185612380505,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 241,
    "start_char": 126479,
    "end_char": 126715,
    "original": "15.3 Effect of Termination . In case of any termination or expiration of this Agreement, all rights and obligations of the Parties shall cease immediately, unless otherwise indicated in this Section below or elsewhere in this Agreement:",
    "modified": "15.3 Consequences of Termination or Expiry: Upon any termination or lapse of this Agreement, all rights and duties of the Parties shall remain intact until explicitly specified in this Section or other parts of this Agreement, unless otherwise terminated earlier by mutual agreement or written notice.",
    "contradiction_score": 0.9900912046432495,
    "kept": true
  },
  {
    "clause_index": 242,
    "start_char": 126715,
    "end_char": 127603,
    "original": "15.3.1 Sale of Inventory . Licensee shall be permitted, at Bioeq\u2019s choice (if this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9, or by Licensee pursuant to Section 15.2.5) or at Licensee\u2019s choice (if this Agreement is terminated by Licensee pursuant to Sections 15.2.1, 15.2.6, 15.2.7 or 15.2.8), to cither (a) continue selling its and its Affiliates\u2019 inventory of Licensed Products existing on the termination effective date in accordance with this Agreement for a maximum period of [***] ([***]) days (in which case all terms and conditions of this Agreement, including Licensee\u2019s obligation to report and pay royalties, shall continue to apply to such continued sale) or (b) sell such inventory to Bioeq at the supply price paid by Licensee to Bioeq for such inventory in accordance with the Manufacturing and Supply Agreement.",
    "ollama_generated": "15.3.1 Disposition of Inventory: Upon termination of this Agreement, as specified in Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9 by Bioeq, or Sections 15.2.1, 15.2.6, 15.2.7, or 15.2.8 by the Licensee, Bioeq shall have the option to dictate the course of action regarding the existing inventory of Licensed Products as of the termination date. This may involve:\n\n(a) Permitting the Licensee to continue selling such inventory in accordance with this Agreement for a maximum period of [***] ([***]) days, during which time all terms and conditions of this Agreement, including the Licensee's royalty reporting and payment obligations, shall remain applicable.\n\n(b) Alternatively, Bioeq may choose to purchase the inventory from the Licensee at the price paid by the Licensee for such inventory, in accordance with the Manufacturing and Supply Agreement. However, it is explicitly noted that this choice does not bind Bioeq to exercise this option. In other words, Bioeq reserves the right to decline the purchase of such inventory.",
    "contradiction_score": 0.14725331962108612,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 255,
    "start_char": 135772,
    "end_char": 135797,
    "original": "16.3 Dispute Resolution .",
    "ollama_generated": "16.3 Arbitration Procedures:\n\nIn the event of any dispute or claim arising out of or in connection with this Agreement (a \"Dispute\"), either Party shall have the right, but not the obligation, to initiate binding arbitration proceedings by providing written notice to the other Party. The parties shall endeavor to settle any Disputes amicably before resorting to arbitration. If the Parties fail to resolve a Dispute within sixty (60) days following written notice of the initial claim, either Party may proceed with the arbitration process in accordance with the applicable rules of the Arbitration Institute of [Country/Region]. The decision of the Arbitrator shall be final and binding on both Parties, subject to appeal only on questions of law.",
    "contradiction_score": 0.03474761173129082,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 256,
    "start_char": 135797,
    "end_char": 136205,
    "original": "16.3.1 The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy or claim arising from or related to this Agreement or the breach thereof. If the Parties cannot resolve such dispute, controversy or claim, either Party may escalate the matter further to the following senior executives of the Parties for final discussion and resolution within [***] ([***]) days:",
    "ollama_generated": "16.3.1 In the event of a dispute, controversy, or claim arising from or related to this Agreement or its breach, one Party has the right, but not the obligation, to initiate discussions with the other Party for resolution. Should mutual agreement not be reached within a reasonable timeframe, either Party may seek the intervention of their respective senior executives, who will strive to resolve the issue amicably. The senior executives shall have [***] ([***]) days to deliberate and arrive at a conclusion.\n\nIn this revised clause, the obligation for both parties to negotiate in good faith has been changed to a right held by one party but not explicitly required of both. Additionally, the timeframe within which senior executives must resolve the dispute has been kept, but the focus has shifted from an expectation that they will resolve it (\"shall\") to a goal they should strive towards (\"will strive to\").",
    "contradiction_score": 0.3582100570201874,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 261,
    "start_char": 139705,
    "end_char": 140575,
    "original": "16.5 Subcontracting . Bioeq shall be entitled to subcontract any of its obligations under this Agreement only with the prior written consent of Licensee, except that such prior written consent of Licensee shall not be required for Bioeq to subcontract to (a) its Affiliates or (b) [***], [***] and [***] and the subcontractors listed in Schedule 16.5, provided that it shall remain liable for the performance of its obligations under this Agreement. Licensee shall be entitled to freely subcontract or delegate any of its rights or obligations under this Agreement to its Affiliates or to Third Parties, provided that (i) all sales of Licensed Products in the Field in the Territory continue to be made by Licensee or its Affiliates (or their wholesalers or distributors) and (ii) Licensee shall remain liable for the performance of its obligations under this Agreement.",
    "ollama_generated": "16.5 Subcontracting Modifications:\n\nLicensee grants Bioeq the authority to subcontract any responsibilities outlined in this Agreement, with the exception that Bioeq will not require Licensee's prior written consent for subcontracting to (a) its Affiliates or (b) entities listed in Schedule 16.5, as well as [***] and [***]. However, Bioeq shall retain liability for fulfilling its obligations under this Agreement.\n\nSimultaneously, Licensee is empowered to freely assign or delegate any of its rights or duties under this Agreement to its Affiliates or external parties, subject to the conditions that:\n\n(i) Sales of Licensed Products within the Territory and Field continue to be handled exclusively by Licensee or its Affiliates (or their authorized wholesalers or distributors).\n\n(ii) Licensee assumes responsibility for meeting all obligations under this Agreement.",
    "contradiction_score": 0.043273936957120895,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 262,
    "start_char": 140575,
    "end_char": 140938,
    "original": "16.6 Construction . This Agreement will be fairly interpreted in accordance with its terms and without any strict construction in favour of or against any Party. The words \u201cinclude\u201d, \u201cincludes\u201d, and \u201cincluding\u201d, \u201csuch as\u201d, \u201cfor example\u201d, or any other words or phrases of enumerative meaning shall be deemed to be followed by the phrase \u201c(but without limitation)\u201d.",
    "ollama_generated": "16.6 Interpretation and Limitations. This Agreement shall be liberally construed, acknowledging a flexible interpretation that may lean in favor of one Party but not to the detriment of the other. The terms \"include\", \"includes\", and \"including\", \"such as\", \"for instance\", or any similar expressions indicating a list are not limiting, and additional items outside of such enumeration may be taken into consideration.\n\nIn this version, the clause shifts the interpretation slightly in favor of one party, acknowledging a flexible interpretation that could potentially benefit either side but with the caveat that it should not disadvantage the other. The phrase \"(but without limitation)\" has been replaced with \"and not to the detriment of the other\" to emphasize this point.",
    "contradiction_score": 0.07969555258750916,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 263,
    "start_char": 140938,
    "end_char": 141561,
    "original": "16.7 Severability . Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be valid and enforceable under Applicable Laws, but if any provision of this Agreement is held to be prohibited by or invalid or unenforceable under Applicable Laws, such provision shall be ineffective only to the extent of such prohibition, invalidity or unenforceability, without invalidating the remainder of such provisions or the remaining provisions of this Agreement, and shall be replaced by a valid and enforceable provisions which comes closest to the commercial intention of the replaced provision.",
    "ollama_generated": "16.7 Survival of Provisions . To the extent permissible under Applicable Laws, each term and condition of this Agreement will survive any determination that one or more provisions herein may be deemed invalid, unenforceable, or prohibited. If a court finds any provision of this Agreement to be invalid, illegal, or unenforceable, such provision shall be deemed modified to the minimum extent necessary to bring it within the applicable law, preserving to the fullest extent possible the intentions of the parties as expressed herein, and the remaining provisions of this Agreement will remain in full force and effect. In the event that a modification is not sufficient, the offending provision will be severed from this Agreement without affecting the validity or enforceability of any other provision.",
    "contradiction_score": 0.06051522493362427,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 264,
    "start_char": 141561,
    "end_char": 142076,
    "original": "16.8 Independent Contractors . Each Party hereby acknowledges that the Parties shall be independent contractors and that the relationship between the Parties shall not constitute a joint venture or Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020 Confidential Execution Version agency. Neither Party shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior consent of the other Party to do so.",
    "ollama_generated": "16.8 Self-Governing Parties . Each Party hereby acknowledges that they act as autonomous entities and their alliance does not establish a partnership or agency relationship. The other Party shall bear no responsibility for any statements, representations, or commitments made by this Party without its express prior authorization. This includes any actions taken that may appear to bind the other Party, without such prior consent being obtained.\n\nIn this revised clause, the shift in responsibility is evident as one party will no longer be held accountable for statements, representations, or commitments made by the other party without explicit prior approval. Additionally, the language has been adjusted to convey a more independent and self-governing relationship between the parties.",
    "contradiction_score": 0.0029891033191233873,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 267,
    "start_char": 142692,
    "end_char": 143556,
    "original": "16.11 Entire Agreement . This Agreement (including the attached Annexes and Schedules) together with the Manufacturing and Supply Agreement and the Pharmacovigilance Agreement described in Section 4.6 contains the entire understanding of the Parties with respect to the subject matter hereof. To the extent of any conflict between the terms and conditions of this Agreement and the terms and conditions of the Manufacturing and Supply Agreement or Pharmacovigilance Agreement, the terms and conditions of this Agreement shall control unless otherwise expressly set forth to the contrary in the Manufacturing and Supply Agreement or Pharmacovigilance Agreement. All other express or implied representations, agreements and understandings with respect to the subject matter hereof, either oral or written, heretofore made, are expressly superseded by this Agreement.",
    "ollama_generated": "16.11 Scope of Agreement. This Agreement (alongside the attached Annexes and Schedules, as well as the Manufacturing and Supply Agreement and the Pharmacovigilance Agreement detailed in Section 4.6) represents the full extent of the Parties' understanding concerning the stipulated subject matter. In any case of inconsistency between the provisions within this Agreement and those in the Manufacturing and Supply Agreement or Pharmacovigilance Agreement, the conflicting terms shall be resolved in favor of the provisions in these other agreements, except where specifically provided otherwise within them. Any additional oral or written declarations, commitments, or interpretations concerning the subject matter, previously made by either Party, are hereby rendered null and void, to be replaced entirely by this Agreement's provisions.",
    "contradiction_score": 0.009735901840031147,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 270,
    "start_char": 144028,
    "end_char": 144200,
    "original": "Bioeq IP AG By: /s/ Hannes Teissl /s/ Nicola Mikulcik Date: November 02, 2019 Name: Hannes Teissl Nicola Mikulcik Title: Board Member Board Member Coherus BioSciences, Inc.",
    "ollama_generated": "Bioeq IP AG By: /s/ Hannes Teissl /s/ Nicola Mikulcik Date: November 02, 2019\n\nName: Nicola Mikulcik, Board Member Nicola Mikulcik, Board Member Coherus BioSciences, Inc.\n\nTitle: Hannes Teissl, Board Member (Primary Responsibility for Intellectual Property Matters Delegated)\n\nRewritten Clause: This clause governs the responsibilities of each party with respect to intellectual property matters. The primary responsibility for such matters shall be delegated to Hannes Teissl, Board Member, who shall manage and oversee these matters on behalf of Bioeq IP AG. However, it is understood that both parties shall cooperate in good faith in the event of any disputes or decisions requiring mutual agreement concerning intellectual property rights. This cooperation includes but is not limited to the provision of necessary information and assistance as may be reasonably requested by either party. Failure to fulfill this obligation may result in consequences as determined by the Board of Directors of Bioeq IP AG, including potential reassignment of responsibilities or legal action.",
    "contradiction_score": 0.16998930275440216,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 272,
    "start_char": 144233,
    "end_char": 145796,
    "original": "Lanfear Date: November 4, Name: Dennis M. Lanfear Title: Chairman & Chief Executive Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020 Confidential Execution Version Annex 1 [***] Agreement Omitted pursuant to Regulation S-K, Item 601(a)(5) Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020 Confidential Execution Version Annex 2 Term Sheet for Manufacturing Supply Agreement Omitted pursuant to Regulation S-K, Item 601(a)(5) Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020 Confidential Execution Version Schedule 1.38 Licensed Patents Omitted pursuant to Regulation S-K, Item 601(a)(5) Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020 Confidential Execution Version Schedule 3.2 Initial Development & Manufacturing Plan Omitted pursuant to Regulation S-K, Item 601(a)(5) Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020 Confidential Execution Version Schedule 3.5.1 Omitted pursuant to Regulation S-K, Item 601(a)(5) Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020 Confidential Execution Version Schedule 6.2(c) Initial Commercialization Commitments Omitted pursuant to Regulation S-K, Item 601(a)(5) Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020 Confidential Execution Version Schedule 6.3 Contents of Commercialization Plan for Planned Activities Omitted pursuant to Regulation S-K, Item 601(a)(5) Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020 Confidential Execution Version Schedule 16.5 Pre-Approved Subcontractors Omitted pursuant to Regulation S-K, Item 601(a)(5) US-DOCS\\112944285.3 Source: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
    "ollama_generated": "Clause:\nLanfear Date: November 4, Name: Dennis M. Lanfear Title: Chairman & Chief Executive\n\nIn the event of any inconsistency or ambiguity in the interpretation of this Agreement, all referenced documents (Annex 1, Annex 2, Schedule 1.38, Schedule 3.2, Schedule 3.5.1, Schedule 6.2(c), Schedule 6.3, Schedule 16.5) shall be construed in favor of the parties, and not against them, in accordance with their spirit rather than the strict letter of their terms. Any omitted or redacted portions under Regulation S-K, Item 601(a)(5) are intended to be included within the scope of this Agreement, unless otherwise specified.\n\nIn case any specific schedules or documents mentioned herein become unavailable due to confidentiality agreements or other reasons, the provisions set forth in this Agreement shall remain binding and effective, with the understanding that the relevant information shall be provided upon request and in accordance with applicable laws and regulations.",
    "contradiction_score": 0.22274532914161682,
    "kept": false,
    "reason": "low_contradiction"
  }
]